PATENT CLAIM ANALYSIS

Application Number: 15891156
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Claim (Index 31):
The compound of  claim 30 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 2.43636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14839580', '14588061', '14959714', '14586826', '14701999']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8912801028739497
- 35 USC 102 Novelty (BERT): 0.7352229559659239
- Combined Prediction Score: 0.8756743881831471
- Mean Citation Score: 891.0495860000003
- Max Citation Score: 973.3439
- Similarity Product: 800.6230954851926

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test